World Library  
Flag as Inappropriate
Email this Article

Neramexane

Article Id: WHEBN0018591609
Reproduction Date:

Title: Neramexane  
Author: World Heritage Encyclopedia
Language: English
Subject: Racemorphan, Phencyclidine, Nitrous oxide, Dextromethorphan, Nitromemantine
Collection: Nmda Receptor Antagonists
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Neramexane

Neramexane
Systematic (IUPAC) name
1,3,3,5,5-pentamethylcyclohexanamine
Clinical data
Legal status
?
Identifiers
CAS number  YesY
ATC code None
PubChem
ChemSpider
UNII  YesY
Chemical data
Formula C11H23N 
Mol. mass 169.307 g/mol
 YesY   

Neramexane is a drug related to memantine,[1] which acts as an NMDA antagonist[2] and has neuroprotective effects.[3] It is being developed for various possible applications, including treatment of tinnitus,[4][5] Alzheimer's disease,[6] drug addiction[7] and as an analgesic.[8] Animal studies have also suggested antidepressant[9] and nootropic[10] actions, so there are a wide range of potential applications this drug may be used for. It also acts as a nicotinic acetylcholine receptor antagonist.[11]

See also

References

  1. ^ Gilling K, Jatzke C, Wollenburg C, Vanejevs M, Kauss V, Jirgensons A, Parsons CG. A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists--in vitro characterization. Journal of Neural Transmission. 2007;114(12):1529-37. PMID 17728997
  2. ^ Danysz W, Parsons CG, Jirgensons A, Kauss V, Tillner J. Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Current Pharmaceutical Design. 2002;8(10):835-43. PMID 11945134
  3. ^ Danysz W, Parsons CG. Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotoxicity Research. 2002 Mar;4(2):119-26. PMID 12829411
  4. ^ ClinicalTrials.gov NCT00405886 Neramexane for Tinnitus
  5. ^ ClinicalTrials.gov NCT00739635 Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus
  6. ^ Rammes G, Schierloh A. Neramexane (merz pharmaceuticals/forest laboratories). IDrugs. 2006 Feb;9(2):128-35. PMID 16523403
  7. ^ Kotlinska J, Biala G, Rafalski P, Bochenski M, Danysz W. Effect of neramexane on ethanol dependence and reinforcement. European Journal of Pharmacology. 2004 Oct 25;503(1-3):95-8. PMID 15496302
  8. ^ Klein T, Magerl W, Hanschmann A, Althaus M, Treede RD. Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia. European Journal of Pain. 2008 Jan;12(1):17-29. PMID 17449306
  9. ^ Kos T, Legutko B, Danysz W, Samoriski G, Popik P. Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice. Journal of Pharmacology and Experimental Therapeutics. 2006 Sep;318(3):1128-36. PMID 16740621
  10. ^ Zoladz PR, Campbell AM, Park CR, Schaefer D, Danysz W, Diamond DM. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacology, Biochemistry and Behaviour. 2006 Oct;85(2):298-306. Epub 2006 Oct 11. PMID 17045636
  11. ^ Plazas PV, Savino J, Kracun S, et al. (July 2007). "Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors" 566 (1-3). pp. 11–9.  


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.